Compare ARK Genomic Revolution ETF (ARKG) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Teradyne, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Teradyne, Inc. trades at $349 (market cap $56.29B). The key difference: Teradyne, Inc. pays a 0.14% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Teradyne, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | TER | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $483.84 |
52-Week Low | $23.09 | $90.15 |
Market Cap | — | $56.29B |
Enterprise Value | — | $56.13B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Teradyne (TER) trades at $359.60, down 0.87% amid a bearish technical signal, though it remains supported by strong fundamentals including a 22.55% net income margin and consistent earnings beats. Recent news highlights AI-driven data center demand boosting revenue, with Q2 2026 EPS expected at $2.04. The company maintains robust profitability metrics like 28.75% ROE, but faces headwinds from negative net cash flow trends and elevated valuation ratios (P/E 66.72).
Outlook: TER's AI and robotics exposure offers growth potential, with a consensus price target of $453.60 implying 26% upside. Risks include semiconductor cycle volatility and high valuations. Analyst sentiment is bullish (64.5% buy ratings), but investors should monitor execution on Q2 earnings and cash flow improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
